Logo

People in the News: Gary Riordan, Kathy Surace-Smith, Michael Aicher

Mar 07, 2013
Premium

NanoString Technologies has appointed Gary Riordan as VP of quality and regulatory affairs and Kathy Surace-Smith as VP and general counsel.

Riordan formerly was VP of quality and regulatory affairs at Sequenom and director of regulatory affairs at Roche's Ventana Medical Systems.

Surace-Smith recently was VP and general counsel and corporate secretary of SonoSite, and she previously was VP and general counsel at Metawave Communications.

Ariosa Diagnostics has appointed Michael Aicher to its board of directors. He is currently the CEO of Omicia. Previously, he was co-founder and CEO of the National Genetics Institute, a wholly owned subsidiary of Laboratory Corporation of America.

Filed under

Diagnostics
NanoString
Roche
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.